Phase I Trial of an Oral/Oral Combination Accruing Patients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 6
Volume 15
Issue 6

GPC Biotech AC is accruing patients with advanced solid tumors onto a phase I trial of satraplatin, its investigational oral platinum agent, in combination with capecitabine (Xeloda). The open label study of the oral/oral combination, led by William Gradishar, MD, of Northwestern University, is expected to enroll approximately 24 patients, the company indicated in a news release.

MARTINSREID/MUNICH, Germany—GPC Biotech AC is accruing patients with advanced solid tumors onto a phase I trial of satraplatin, its investigational oral platinum agent, in combination with capecitabine (Xeloda). The open label study of the oral/oral combination, led by William Gradishar, MD, of Northwestern University, is expected to enroll approximately 24 patients, the company indicated in a news release.

Articles in this issue
Triple-Negative Cancers More Common in Young Black Pts
Artists Turn Flowers & Curves Into 'Forms' and 'Figures'
Study to Examine Outcomes Disparities in Pediatric ALL
Thalidomide Has 'Changed the Paradigm' in Myeloma Rx
CA4P Gets Orphan Drug Status
Testicular Ca Survivors at Increased Risk for CV Events
A Novel Brings a Cancer Research Laboratory to Life
NCCN Reveals New Venous Thromboembolism Guideline
Lapatinib New Option for Metastatic HER2+ Breast Ca
FDA Approves Dacogen for Treating All MDS Subtypes
Noninvasive Ablation Relieves Chronic Chest Wall Pain
GVAX Receives Fast-Track Status
Medicare CAP Vendor Selected
Selective IGF-1R Inhibitor Blocks Colon Cancer Growth
US Cancer Mortality Drops
Recent Videos
4 experts in this video
7 experts are featured in this series.
2 KOLs are featured in this series.
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
2 experts are featured in this series.
2 experts are featured in this series.
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
A new partnership agreement involving AI use may help spread radiotherapeutic standards from academic centers to more patients in community-based practices.
Related Content
The FDA decision is based on data from a pooled analysis of phase 1/2 study data from 2 trials evaluating the agent in advanced/metastatic PROC.

JSKN003 Receives FDA Fast Track Designation in Advanced PROC

Roman Fabbricatore
October 28th 2025
Article

The FDA decision is based on data from a pooled analysis of phase 1/2 study data from 2 trials evaluating the agent in advanced/metastatic PROC.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

The developers will present these data at an upcoming medical meeting and plan to begin discussions with regulatory authorities.

Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC

Tim Cortese
October 28th 2025
Article

Belzutifan/lenvatinib also showed a favorable trend towards improvement for overall survival in this advanced renal cell carcinoma population.

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Anne Chiang, MD
October 20th 2025
Podcast

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Granulosa cell tumors exhibit late recurrence and rare hepatic metastasis, emphasizing the need for lifelong surveillance in affected patients.

Late Hepatic Recurrence From Granulosa Cell Tumor: A Case Report

Prosper Akankwasa, MBBS;Jackson Kakooza, MBBS;Aisha Abdullahi Ahmed, MBBS;Catherine R. Lewis, MD, PhD
October 28th 2025
Article

Granulosa cell tumors exhibit late recurrence and rare hepatic metastasis, emphasizing the need for lifelong surveillance in affected patients.

Allireza Alloo, MD

An Oncodermatologist’s Perspective on Dermatological Toxicities in Breast Cancer

Tim Cortese
October 27th 2025
Article

Onco-dermatology enhances patient care and quality of life by addressing skin toxicities in breast cancer treatments through expert management and collaboration.